This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization Europe
5-8 December 2022
Beurs van BerlageAmsterdam, Netherlands

Victor Chen
Principal Scientist at REGENXBIO


Victor Chen is currently working as a principal scientist at REGENXBIO. He leads a team of scientists to provide analytical development support for gene therapy programs at all stages of development and manufacturing. Prior to this, he worked at GlaxoSmithKline in a thriving team of biopharma scientists across discovery, development, and manufacturing. He has a broad industrial experience in the development and licensure of various therapeutic biologics including fusion proteins, mAbs, ADCs, and gene & cell therapies. Victor received his Ph.D. in 2008 from Barnett Institute for Chemical & Biological Analysis at Northeastern University.

Agenda Sessions

  • Critical Quality Attributes Risk Assessment for Recombinant Adeno-Associated Virus Vector